Shared bone-metastasis hub covering actionable research summaries, standard bone-targeted therapies, integrative strategies, protocol notes, and community member experiences.
This is the main hub for bone-metastasis topics on the site.
Use the links below to move through the section quickly.
If you want the standard-treatment anchor first, start with Denosumab and Zoledronic Acid.
If you want the upstream RANKL/OPG biology behind bone turnover, go to L.reuteri hits RANKL/Bone Axis.
Dormant cancer cells in bone: what this 2025 review reveals: Straightforward summary of the 2025 Bakir review, including dormancy, reactivation, and practical takeaways.
Denosumab and Zoledronic Acid: Core comparison of the main bone-targeted standard therapies, with substance names first.
L.reuteri hits RANKL/Bone Axis: Mechanistic page on the gut–bone immune axis, RANKL/OPG signalling, aromatase-inhibitor bone loss, and why L. reuteri is being discussed alongside standard bone protection.
Integrative and Off-Label Strategies: Notes on RANKL, NF-κB, melatonin, propranolol, and related support ideas.
FOXM1 in Bone Metastasis: Why FOXM1 matters in metastasis, bone biology, and possible targeting strategies.
Bone Support and Protocol Notes: Timing, practitioner notes, and practical implementation points.
Group Member Tips and Supporting Evidence: Community-shared tips paired with supporting evidence, including denosumab, zoledronic acid, WSZG, and D-limonene notes.
SABR for Bone Metastases 2025 Study Summary: Summary of the 2025 small-scale human study on SABR for bone metastases.
This material is educational.
Discuss treatment changes, supplements, and off-label strategies with your healthcare team before acting.
Last updated
Was this helpful?
Was this helpful?
